The WNT system: background and its role in bone

• Published in: Journal of internal medicine Vol. 277; no. 6; pp. 630 - 649
• Main Authors: Lerner, U. H., Ohlsson, C.
• Format: Journal Article
• Language: English
• Published: England 01-06-2015
• Subjects: Anabolic Agents - therapeutic use; Animals; bone; Bone and Bones - metabolism; Bone Remodeling - drug effects; Cell Differentiation; Endocrinology and Diabetes; Endokrinologi och diabetes; Evidence-Based Medicine; Humans; osteoblast; Osteoblasts - metabolism; osteoclast; Osteogenesis - drug effects; Osteoporosis - prevention & control; sclerostin; WNT; Wnt Proteins - antagonists & inhibitors; Wnt Proteins - genetics; Wnt Proteins - metabolism; Wnt Signaling Pathway; bone; osteoblast; WNT; osteoclast; sclerostin
• ISSN: 0954-6820; 1365-2796; 1365-2796
• DOI: 10.1111/joim.12368

WNTs are extracellular proteins that activate different cell surface receptors linked to canonical and noncanonical WNT signalling pathways. The Wnt genes were originally discovered as important for embryonic development of fruit flies and malignant transformation of mouse mammary cancers. More recently, WNTs have been implicated in a wide spectrum of biological phenomena and diseases. During the last decade, several lines of clinical and preclinical evidence have indicated that WNT signalling is critical for trabecular and cortical bone mass, and this pathway is currently an attractive target for drug development. Based on detailed knowledge of the different WNT signalling pathways, it appears that it might be possible to develop drugs that specifically target cortical and trabecular bone. Neutralization of a bone‐specific WNT inhibitor is now being evaluated as a promising anabolic treatment for patients with osteoporosis. Here, we provide the historical background to the discoveries of WNTs, describe the different WNT signalling pathways and summarize the current understanding of how these proteins regulate bone mass by affecting bone formation and resorption.